Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

398
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
398
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

1.1K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.1K
Factors Affecting Drug Distribution: Tissue Permeability01:30

Factors Affecting Drug Distribution: Tissue Permeability

649
The drug distribution process within the human body is a complex interplay of various physicochemical properties inherent to the drugs. These properties, including molecular size, ionization degree, partition coefficient, and stereochemical nature, significantly impact how drugs permeate biological membranes to reach their target tissues.
Small molecules with a molecular weight below 500 to 600 Daltons can easily pass through the capillary membrane, gaining access to different tissues. Larger...
649
C4 Pathway and CAM01:27

C4 Pathway and CAM

49.1K
Most plants use the C3 pathway for carbon fixation. However, some plants, such as sugar cane, corn, and cacti that grow in hot conditions, use alternative pathways to fix carbon and conserve energy loss due to photorespiration. Photorespiration is the process that occurs when the oxygen concentration is high. Under such conditions, the rubisco enzyme in the Calvin cycle binds O2 instead of CO2, which halts photosynthesis and consumes energy.
C4 Pathway
The C4 pathway is used by plants such as...
49.1K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

522
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
522

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brain Metabolic Signatures of Amyloid-β and Tau Pathology in Corticobasal Syndrome: A Multimodal Biomarker Study.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Repurposing atorvastatin for uterine leiomyosarcoma: mevalonate pathway inhibition yields preclinical antitumor efficacy.

Acta pharmacologica Sinica·2026
Same author

PROTAC-mediated PCSK9 degradation attenuates atherosclerosis and improves plaque composition via suppression of NF-κB/TNF-α pathway.

BMC medicine·2026
Same author

Cerebral metabolic trajectories alterations in multiple system atrophy: A longitudinal FDG-PET study.

Journal of Parkinson's disease·2026
Same author

UFMylation in lipid metabolism disorders-associated diseases.

Molecular biology reports·2026
Same author

SIRT3 Activation by SGLT2 Inhibitor Mitigates Endothelial-To-Mesenchymal Transition in Dahl Salt-Sensitive Rats Induced by High-Salt Diet.

American journal of hypertension·2025

Related Experiment Video

Updated: Jan 30, 2026

Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis
09:55

Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis

Published on: October 25, 2024

1.5K

Tissue factor pathway inhibitor in atherosclerosis.

Hou-Qin Yuan1, Ya-Meng Hao1, Zhong Ren1

  • 1Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerosis of Hunan Province, Hengyang Medical College, University of South China, Hengyang City, Hunan Province 421001, PR China.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|January 30, 2019
PubMed
Summary

Tissue factor pathway inhibitor (TFPI) inhibits atherosclerosis by regulating coagulation. This review explores TFPI's effects on vascular cells and inflammation, and its clinical impact on atherogenesis.

Keywords:
AtherosclerosisTissue factor pathway inhibitor

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.3K
Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

40.3K

Related Experiment Videos

Last Updated: Jan 30, 2026

Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis
09:55

Three-Dimensional Imaging of Aortic Tissues in Atherosclerosis

Published on: October 25, 2024

1.5K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.3K
Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

40.3K

Area of Science:

  • Cardiovascular Biology
  • Thrombosis and Hemostasis
  • Atherosclerosis Research

Background:

  • Atherosclerosis development involves complex pathways including coagulation.
  • Tissue factor pathway inhibitor (TFPI) plays a regulatory role in the tissue factor (TF) mediated coagulation cascade.
  • Understanding TFPI's multifaceted roles is crucial for therapeutic strategies against atherosclerosis.

Purpose of the Study:

  • To review recent findings on TFPI's inhibitory effects on key cellular processes in atherosclerosis.
  • To examine the impact of TFPI levels and genetic variations on clinical atherogenesis.
  • To elucidate the mechanisms by which TFPI inhibits atherosclerosis and its clinical relevance in atherothrombosis.

Main Methods:

  • Literature review focusing on recent scientific findings.
  • Analysis of studies investigating TFPI's effects on endothelial cells, vascular smooth muscle cells, and inflammatory cells.
  • Examination of research on TFPI levels and genetic polymorphisms in relation to atherogenesis.

Main Results:

  • TFPI demonstrates inhibitory effects on endothelial cell activation, VSMC proliferation and migration, inflammatory cell recruitment, and extracellular matrix remodeling.
  • TFPI levels and genetic polymorphisms are associated with clinical atherogenesis.
  • TFPI's mechanism of action involves regulating the TF-mediated coagulation pathway.

Conclusions:

  • TFPI is a significant inhibitor of atherosclerosis development through its effects on vascular and inflammatory processes.
  • TFPI's role extends to clinical atherogenesis, influenced by its levels and genetic makeup.
  • Further research into TFPI mechanisms and clinical effects may offer novel therapeutic targets for atherothrombosis.